SagarDSardesaiMD

Oncology • Columbus, OH

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Sardesai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sardesai's full profile

Already have an account?

Office
1145 Olentangy River Rd
Columbus, OH 43212
Phone+1 614-293-0066

Fax+1 614-293-7264

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
University at BuffaloResidency, Internal Medicine, 2010 - 2013
Topiwala National Medical CollegeClass of 2008

Certifications & Licensure

OH State Medical License 2016 - 2026
IN State Medical License 2013 - 2017
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients Start of enrollment: 2017 Aug 15
Withdrawn
Not Applicable

Publications & Presentations

PubMed

18 citations
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
Sagar Sardesai, Alexandra Thomas, Christopher Gallagher, Filipa Lynce, Yvonne L. Ottaviano
Clinical Cancer Research. 2021-11-01
12 citations
Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.
Daniel G. Stover, Raquel E. Reinbolt, Elizabeth J. Adams, Sarah Asad, Katlyn Tolliver
JCO Precision Oncology. 2019-11-18
561 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M Tolaney, Delphine Loirat, Kevin Punie
The New England Journal of Medicine. 2021-04-21

Lectures

Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Best Diet for Breast CancerJuly 16th, 2021
Dana-Farber's New BRCA Cancer Center Connects More Patients to Clinical TrialsAugust 20th, 2020
Breast Cancer Survivor Explains How 'Pinkwashing' Hurts Those with Breast CancerOctober 19th, 2017
Join now to see all